Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
40results about "Neurotensin" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Conjugates of neurotensin or neurotensin analogs and uses thereof
ActiveUS20100256055A1Reduce the frequency of occurrenceReduce severityNervous disorderPeptide/protein ingredientsDiseaseAgonist
The present invention features a compound having the formula A-X—B, where A is peptide vector capable of enhancing transport of the compound across the blood-brain barrier or into particular cell types, X is a linker, and B is a peptide therapeutic selected from the group consisting of neurotensin, a neurotensin analog, or a neurotensin receptor agonist. The compounds of the invention can be used to treat any disease in which increased neurotensin activity is useful and can be used to induce hypothermia or analgesia.
Owner:ANGLACHEM INC
Compositions and methods for the transport of therapeutic agents
InactiveUS20120277158A1Reducing and eliminating risk of developingReduce the numberPowder deliveryObesity gene productsTherapeutic effectCell type
The present invention is directed to conjugates that include a polypeptide capable of crossing the blood-brain barrier or entering one or more cell types attached to a transport vector, i.e., a composition capable of transporting an agent (e.g., a therapeutic agent). In certain cases, the polypeptides are directly conjugated to a lipid or polymeric vector to allow targeted application of a therapeutic agent to treat, for example, a cancer, a neurodegenerative disease, or a lysosomal storage disorder.
Owner:ANGLACHEM INC
Nts-polyplex nanoparticles system for gene therapy of cancer
InactiveUS20150307554A1Specificity of thinAvoid developmentPowder deliveryPeptide/protein ingredientsCancer cellWhole body
The present invention describes a system of gene carrier nanoparticles capable of specifically internalize into cancer cells, eg, cancer cells involved in breast cancer, in vitro and in vivo. The system described allows the introduction of therapeutic genes specifically into target cells through NSTR1 receptor-mediated endocytosis of said system, making it possible to provide treatment for this type of conditions, for example by systemic, intravenous, or in situ administration.
Owner:CASTILLO RODRIGUEZ ROSA ANGELICA
Algorithmic design of peptides for binding and/or modulation of the functions of receptors and/or other proteins
InactiveUS20050119454A1Improve the immunityImprove actionCell receptors/surface-antigens/surface-determinantsPeptide/protein ingredientsDiseaseProtein target
Methods of synthesizing a peptide or peptide-like molecule to a polypeptide or protein target based on mode-matching each member of a set of peptide constituents of the peptide or peptide-like molecule to peptide constituents of the target polypeptide or protein target for treatment of neurological diseases.
Owner:CIELO INST
Neo-tryptophan
The invention provides a novel amino acid, neo-tryptophan, as well as polypeptides containing this novel amino acid such as neurotensin analogs. In addition, the invention provides neo-tryptophan derivatives, serotonin-like neo-tryptophan derivatives, and polypeptides containing such derivatives. The invention also provides methods for making neo-tryptophan, neo-tryptophan derivatives, serotonin-like neo-tryptophan derivatives, and compositions containing these compounds. Further, the invention provides methods for inducing a neurotensin response in a mammal as well as methods for treating a mammal having a serotonin recognition molecule.
Owner:MAYO FOUND FOR MEDICAL EDUCATION & RES
Peptide analogs that are potent and selective for human neurotensin preceptor subtype 2
InactiveUS20090062212A1Lower blood pressureNervous disorderPeptide/protein ingredientsMedicineNeurotensin receptor
Neurotensin analogs selective for neurotensin receptor subtype 2 are described. These include hexapeptides (NT(8-13)) and pentapeptides (NT(9-13)) having a D-3,1-naphthyl-alanine, D-3,2-naphthyl-alanine, an alanine derivative such as cyclohexylalanine, or 1,2,3,4-tetrahydroisoquinoline at position 11. Methods of treating pain by administering these neurotensin analogs are also described.
Owner:MAYO FOUND FOR MEDICAL EDUCATION & RES
Short and d-amino acid-containing polypeptides for therapeutic conjugates and uses thereof
InactiveUS20130280281A1Improve efficiencyEfficient transportPeptide/protein ingredientsPeptide sourcesDiseaseMoiety
The present invention relates to short polypeptides (e.g., fewer than 19 amino acids in length) and longer polypeptides (e.g., 19 or more amino acids in length) having one or more D-amino acids as targeting moieties. These polypeptides, when conjugated to agents (e.g., therapeutic agents or transport vectors) are capable of transporting the agents across the BBB or into particular cell types. In particular, the short polypeptides can include one or more D-amino acids. These compounds are therefore particularly useful in the treatment of neurological diseases or diseases associated with particular cell types, organs, or tissues.
Owner:ANGLACHEM INC
Labeled neurotensin derivatives
InactiveUS20050191240A1Increase serum stabilityUseful purposePeptide/protein ingredientsRadioactive preparation carriersEnzymatic degradationStereochemistry
Peptide analogs of neurotensin are disclosed which are resistant to enzymatic degradation and which retain high binding affinity for neurotensin receptors. Pharmaceutical compositions of these compounds are useful for diagnostic and therapeutic purposes.
Owner:ADVANCED ACCELERATOR APPL USA
Compositions and methods for the transport of therapeutic agents
InactiveUS20150174267A1Improve compoundExtended half-lifePowder deliveryObesity gene productsTherapeutic effectCell type
The present invention is directed to conjugates that include a polypeptide capable of crossing the blood-brain barrier or entering one or more cell types attached to a transport vector, i.e., a composition capable of transporting an agent (e.g., a therapeutic agent). In certain cases, the polypeptides are directly conjugated to a lipid or polymeric vector to allow targeted application of a therapeutic agent to treat, for example, a cancer, a neurodegenerative disease, or a lysosomal storage disorder.
Owner:ANGLACHEM INC
Neo-tryptophan
The invention provides a novel amino acid, neo-tryptophan, as well as polypeptides containing this novel amino acid such as neurotensin analogs. In addition, the invention provides neo-tryptophan derivatives, serotonin-like neo-tryptophan derivatives, and polypeptides containing such derivatives. The invention also provides methods for making neo-tryptophan, neo-tryptophan derivatives, serotonin-like neo-tryptophan derivatives, and compositions containing these compounds. Further, the invention provides methods for inducing a neurotensin response in a mammal as well as methods for treating a mammal having a serotonin recognition molecule.
Owner:MAYO FOUND FOR MEDICAL EDUCATION & RES
Non-natural amino acids and neurotensin analogues
InactiveUS20080234202A1Selective and long-lasting biological activityNervous disorderPeptide/protein ingredientsArgininePeptide sequence
Owner:THE MEDICAL UNIV OF SOUTH CAROLINA +1
Cell penetrating stapled peptide, manufacturing method therefor, and use thereof
ActiveUS20170342108A1Effective penetrationReduce the numberPeptide-nucleic acidsOrganic active ingredientsStapled peptideHydrophobe
The present invention relates to a stapled peptide, a preparation method thereof and the use thereof, and more specifically to an amphipathic alpha-helical stapled peptide comprising hydrophobic amino acids and hydrophilic amino acids, a preparation method thereof, and the use thereof for intracellular delivery of an active substance.
Owner:SEOUL NAT UNIV R&DB FOUND
Algorithmic design of peptides for binding and/or modulation of the functions of receptors and/or other proteins
Owner:CIELO INST
Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy
The present disclosure relates to peptide compounds and conjugate compounds, processes, methods and uses thereof for treating cancer and increasing cellular internalization of said peptide compounds. The peptide compounds are selected from the following group consisting of; GVRAKAGVRNMFKSESY as set forth in SEQ ID NO: 9; GVRAKAGVRN(Nle)FKSESY as set forth in SEQ ID NO: 10; and YKSLRRKAPRWDAPLRDPALRQLL as set forth in SEQ ID NO: 11; and wherein at least one protecting group and / or at least one labelling agent is connected to said peptide compound.
Owner:TRANSFERT PLUS S E C
Peptide analogs
InactiveUS20190153059A1Prevent unwanted side effectPeptide/protein ingredientsAntibody mimetics/scaffoldsG protein-coupled receptorReceptor regulator activity
Analogs for CLR / RAMP receptor ligands are provided that have agonist, superagonist, antagonist, super-antagonist, or multiple receptor modulatng activity. The analogs can be selective for one or more CLR / RAMP receptors, or can be pan-specific for multiple G protein-coupled receptors.
Owner:ADEPTHERA LLC
Multi-site modified enkephalin and neurotensin (8-13) coupled cycled hybrid peptide, compounding method and application thereof
ActiveCN109232748AImprove resistance to enzymatic hydrolysisImprove transportation capacityNervous disorderPeptide/protein ingredientsMulti siteWang resin
The invention provides a multi-site modified enkephalin and neurotensin (8-13) coupled cycled hybrid peptide, a compounding method and an application thereof and relates to a cycled hybrid peptide, the compounding method and the application thereof. The invention aims to solve the problems of inferior anti-enzymolysis capacity and non-ideal anti-neuropathic pain effect of present opioids. The hybrid peptide is a hybrid peptide 1, a hybrid peptide 2, a hybrid peptide 3 or a hybrid peptide 4. The preparation method comprises the following steps: 1) pre-treating 'Fmoc' protected Wang resin; 2) removing 'Fmoc' protecting groups; 3) triggering condensation reaction of amino acid; 4) prolonging peptide chain; 5) forming a disulfide bond; 6) cutting peptide chain from the resin; 7) desalting andpurifying crude peptide. According to the invention, the biological stability of hybrid peptide can be enhanced and an anti-neuropathic pain effect can be endowed, through multi-site unnatural amino acid substitution and cyclizing modification. The hybrid peptide provided by the invention can be used for preparing drugs for relieving neuropathic pain.
Owner:黑龙江省工研院资产经营管理有限公司
Methods and compounds for targeting sortilin receptors and inhibiting vasculogenic mimicry
PendingUS20220000971A1Increasing stability and bioavailabilityImprove tolerancePeptide/protein ingredientsLibrary screeningReceptorChemical compound
The present disclosure relates to peptide compounds and conjugate compounds, processes, methods and uses thereof for treatment of cancer or aggressive cancer. For example, the compounds can comprise compounds of formula X1X2X3X4X5GVX6AKAGVX7NX8FKSESY (I) (SEQ ID NO: 1) (X9)nGVX10AKAGVX11NX12FKSESY (II) (SEQ ID NO: 2) YKX13LRRX14APRWDX15PLRDPALRX16X17L (III) (SEQ ID NO: 3) YKX18LRR(X19)nPLRDPALRX20X21L (IV) (SEQ ID NO: 4) IKLSGGVQAKAGVINMDKSESM (V) (SEQ ID NO: 5) IKLSGGVQAKAGVINMFKSESY (VI) (SEQ ID NO: 6) IKLSGGVQAKAGVINMFKSESYK (VII) (SEQ ID NO: 7) GVQAKAGVINMFKSESY (VIII) (SEQ ID NO: 8) GVRAKAGVRNMFKSESY (IX) (SEQ ID NO: 9) GVRAKAGVRN(Nle)FKSESY (X) (SEQ ID NO: 10) YKSLRRKAPRWDAPLRDPALRQLL (XI) (SEQ ID NO: 11) YKSLRRKAPRWDAYLRDPALRQLL (XII) (SEQ ID NO: 12) YKSLRRKAPRWDAYLRDPALRPLL (XIII) (SEQ ID NO: 13) wherein X1 to X21 and n can have various different values and wherein at least one protecting group and / or at least one labelling agent is optionally connected to said peptide compound at an N- and / or C-terminal end, for use in inhibiting vasculogenic mimicry and / or for treating a cancer.
Owner:TRANSFERT PLUS S E C
Nts-polyplex nanoparticles system for gene therapy of cancer
Owner:CENT DE INVESTIGACION & DE ESTUDIOS AVANZADOS DEL INST POLITECNICO NACIONAL
Vinylsulfone-based 18F-labeling Compositions and Methods and Uses Thereof
ActiveUS20160015838A1Excellent coupling potentialPeptide/protein ingredientsOrganic compound preparationThio-18f labeling
A thio-selective radioactive labeling agent has the following general formula:*R-L-VS,wherein said *R is a radioisotope, L is a linking group, and VS is a vinylsulfone functional group.
Owner:UNIV OF SOUTHERN CALIFORNIA +1
Labeled neurotensin derivatives
InactiveUS7015306B2Peptide/protein ingredientsRadioactive preparation carriersTherapeutic intentEnzymatic degradation
Peptide analogs of neurotensin are disclosed which are resistant to enzymatic degradation and which retain high binding affinity for neurotensin receptors. Pharmaceutical compositions of these compounds are useful for diagnostic and therapeutic purposes.
Owner:ADVANCED ACCELERATOR APPL USA
Macrocyclic compounds and methods of preventing or treating pain
The present invention provides a macrocyclic compound of formula (I)compositions and kits comprising this compound and their use for preventing or treating pain, or inducing hypothermia or hypotension.
Owner:SOCPRA SCI SANTE & HUMAINES S E C
Radiopharmaceuticals and methods of use thereof
PendingUS20200316233A1Peptide/protein ingredientsAntibody mimetics/scaffoldsRadioactive drugOncology
Targeted pharmaceuticals, particularly targeted radiopharmaceuticals, are provided which possess extended tumor retention time.
Owner:BOARD OF RGT UNIV OF NEBRASKA
Neurotensin-derived branched peptides and uses thereof
InactiveCN102271713ASlow tumor growthPeptide/protein ingredientsGeneral/multifunctional contrast agentsNeurotensinCancer research
Owner:路易莎·布拉奇 +3
Methods and compounds for targeting sortilin receptors and inhibiting vasculogenic mimicry
PendingCN113286820ACell receptors/surface-antigens/surface-determinantsPeptide/protein ingredientsReceptorChemical compound
The present disclosure relates to peptide compounds and conjugate compounds, processes, methods and uses thereof for treatment of cancer or aggressive cancer. For example, the compounds can comprise compounds of formula X1 X2X3X4X5GVX6AKAGVX7NX8FKSESY (I) (SEQ ID NO: 1) (X9)nGVX10AKAGVX11NX12FKSESY (II) (SEQ ID NO: 2) YKX13LRRX14APRWDX15PLRDPALRX16X17L (III) (SEQ ID NO: 3) YKX18LRR(X19)nPLRDPALRX20X21L (IV) (SEQ ID NO: 4) IKLSGGVQAKAGVINMDKSESM (V) (SEQ ID NO: 5) IKLSGGVQAKAGVINMFKSESY (VI) (SEQ ID NO: 6) IKLSGGVQAKAGVINMFKSESYK (VII) (SEQ ID NO: 7) GVQAKAGVINMFKSESY (VIII) (SEQ ID NO: 8) GVRAKAGVRNMFKSESY (IX) (SEQ ID NO: 9) GVRAKAGVRN(Nle)FKSESY (X) (SEQ ID NO: 10) YKSLRRKAPRWDAPLRDPALRQLL (XI) (SEQ ID NO: 11) YKSLRRKAPRWDAYLRDPALRQLL (XII) (SEQ ID NO: 12) YKSLRRKAPRWDAYLRDPALRPLL (XIII) (SEQ ID NO: 13) wherein X1 to X21 and n can have various different values and wherein at least one protecting group and / or at least one labelling agent is optionally connected to said peptide compound at an N- and / or C-terminal end, for use in inhibiting vasculogenic mimicry and / or for treating a cancer.
Owner:TRANSFERT PLUS S E C
Peptide analogs
ActiveUS11390657B2Prevent unwanted side effectPeptide/protein ingredientsAntibody mimetics/scaffoldsReceptor regulator activityAgonist
Owner:ADEPTHERA LLC
A kind of neuropeptide and its synthesis method and application
ActiveCN106831948BEffective treatment treatmentImproving deficits in social memoryNervous disorderPeptide/protein ingredientsNervous systemArginine
Owner:SOUTHEAST UNIV
Vinylsulfone-based 18F-labeling compositions and methods and uses thereof
InactiveUS10471161B2Excellent coupling potentialOrganic chemistry methodsRadioactive preparation carriersThio-18f labeling
A thio-selective radioactive labeling agent has the following general formula:*R-L-VS,wherein said *R is a radioisotope, L is a linking group, and VS is a vinylsulfone functional group.
Owner:UNIV OF SOUTHERN CALIFORNIA +1
Dynorphin A (1-8) and neurotensin (8-13) coupled cyclic hybrid peptide, as well as synthesizing method and application thereof
ActiveCN109232747AImprove resistance to enzymatic hydrolysisImprove transportation capacityNervous disorderPeptide/protein ingredientsAmino acid substitutionWang resin
The invention provides a dynorphin A (1-8) and neurotensin (8-13) coupled cyclic hybrid peptide, as well as a synthesizing method and an application thereof, relates to cyclic hybrid peptides, as wellas a synthesizing method and an application thereof, and aims at solving the problems of relatively poor biological stability and poor neuropathic pain relieving effect of existing opioid medicines.The hybrid peptide has an amino acid sequence of Dmt-Gly-c(Cys-NMePhe-Leu-Arg-Arg-Ile-Cys)-Gly-NMeArg-Lys-Pro-Trp-Tle-Leu. The method comprises the following steps: 1, pretreating 'Fmoc' protected Wang resin; 2, removing the 'Fmoc' protective group; 3, performing an amino acid condensation reaction; 4, prolonging a peptide chain; 5, forming a disulfide bond; 6, cutting off the peptide chain from resin; and 7, desalting and purifying crude peptide. The biological stability of hybrid peptide can be enhanced through multi-site unnatural amino acid substitution and cyclic modification, and the cyclic hybrid peptide has an effect of relieving neuropathic pains. The hybrid peptide is used for preparing neuropathic pain relieving medicines.
Owner:黑龙江鉴成生物技术有限公司
Activated neurotensin molecules and the uses thereof
ActiveUS9821072B2Improve propertiesQuick effectNervous disorderPeptide/protein ingredientsMedicineReducing bodies
The present invention relates to activated neurotensin, pharmaceutical compositions comprising the same, and the uses thereof. The compounds and compositions of the invention may be used, e.g., to reduce body temperature, attenuate or halt seizures, reduce excitotoxicity, promote neuroprotection, reduce neuroinflammation and aberrant axonal sprouting or reduce pain.
Owner:VECT HORUS +1
Fluorescent ligands for GPCR arrays
InactiveUS20060148101A1Robust GPCR microarray applicationsBiological material analysisBiological testingBODIPYMotilin
Microarrays employing a fluorescent ligand including a material having a binding affinity in the range of about 0.01 to about 25 nM, or about 0.1 to about 10 nM; a specificity to its cognate receptor in the range of about 50 to about 99%, or about 65 to about 99%; a cross-activity to other receptors of 0 to about 20%, or 0 to about 10%; a net charge per ligand of about −3 to about +5, or more preferably, about −2 to about +2 or most preferably for small compound ligands about −1 to about +2. The ligand may also have a hydrophobicity in the range of about 3 to about 55 minutes eluting time (as measured under specified eluting conditions). In some embodiments, the ligand includes fluorescently labeled motilin 1-16 labeled with Bodipy-TMR, rhodamine or Cy5-. Other embodiments include fluorescently labeled Cy5-naltrexone, Cy5-neurotensin 2-13, N-terminal labeled neurotensin 2-13 or lys-labeled labeled neurotensin 2-13.
Owner:CORNING PATENT DEPT
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com